NASDAQ / Three Largest Biotech IPOs in 2022
Initial public offerings (IPOs) —a vital source of cash for up-and-coming biotechs— saw a huge decline in 2022 with respect to the previous year. After 2021’s record of more than…
Address: 781 Chestnut Ridge Rd, Morgantown, WV 26505,United States of America
Tel: 1-800-RX-MYLAN
Mylan Pharmaceuticals, a subsidiary of Mylan Inc. based in Morgantown, W.Va., is a market leader in researching, developing, manufacturing, marketing and distributing generic pharmaceutical products in a variety of sophisticated dosage forms. Since 1961, Mylan Pharmaceuticals has held a long-standing reputation for quality, integrity and exemplary service and has maintained its commitment to increasing and protecting consumer access to affordable pharmaceuticals.
Mylan Pharmaceuticals has one of the largest product portfolios in the U.S., consisting of more than 200 products. According to IMS Health, one of every 12 prescriptions dispensed in the U.S. is a Mylan product.1 The company pioneered and continues to specialize in groundbreaking delivery technologies and difficult-to-manufacture and -formulate pharmaceuticals that treat diseases ranging from angina to arthritis, depression to diabetes, pain to Parkinson’s disease, and schizophrenia to sleep disorders.
Initial public offerings (IPOs) —a vital source of cash for up-and-coming biotechs— saw a huge decline in 2022 with respect to the previous year. After 2021’s record of more than…
Antimicrobial resistance (AMR), or the resistance of pathogens to antibiotics, antivirals, antifungals and antiparasitics has been declared by the World Health Organization (WHO) as one of the top 10 global…
David H. Crean, Managing Partner for Cardiff Advisory, discusses the economic impact of the signing and implementation of the Inflation Reduction Act (IRA) on the biopharmaceutical industry and innovation. …
Insights from US President Joe Biden’s chief medical adviser, Anthony Fauci, who served on the White House Coronavirus Task Force at the height of the pandemic, on the end of…
After Big Pharma lobby groups suffered a major drug pricing blow earlier this year with the passage of the US Inflation Reduction Act (IRA), pharma industry heavyweight AbbVie is withdrawing…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
Clinical trial diversity not only allows for a better understanding of the safety and efficacy of new therapies in population subgroups but also plays a significant role in reducing health…
Reflecting on a transformational decade at the helm of the Drug Information Association (DIA), Barbara Lopez Kunz highlights some of the key achievements and most significant trends that have emerged…
A boom in decentralised clinical trials was an unexpected effect of the COVID-19 pandemic and subsequent lockdowns. However, these trials require expertise and technology that can differ significantly from those…
Fortune’s new 50 Most Powerful Women in Business list features four representatives of Big Pharma, as well as a further four from powerful US health insurance corporations. The annual…
The FDA’s recent accelerated approval for Bluebird Bio’s gene therapy Skysona and its US list price of USD three million per treatment has reignited the global debate around drug pricing.…
AstraZeneca’s CEO Pascal Soriot warns that the new US legislation controlling drug prices would reduce innovators’ capacity to recover drug development investments and therefore discourage innovation, especially for drugs with smaller…
See our Cookie Privacy Policy Here
